Nanomedicine for vaccination and diagnosis of diseases

NanomedicineVol. 16, No. 3 Journal WatchNanomedicine for vaccination and diagnosis of diseasesStefan Lyer, Christina Janko, Ralf P Friedrich, Iwona Cicha, Rainer Tietze, Harald Unterweger & Christoph AlexiouStefan LyerDepartment Otorhinolaryngology, Head Neck Surgery, Section Experimental Oncology Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Glueckstr. 10a, Erlangen 91054, GermanySearch more papers by this author, JankoDepartment FriedrichDepartment Cicha https://orcid.org/0000-0002-7399-5307Department TietzeDepartment UnterwegerDepartment author Alexiou*Author correspondence: E-mail Address: [email protected] authorPublished Online:3 Feb 2021https://doi.org/10.2217/nnm-2020-0483AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: cancerdisease detectionimmunotherapyvaccinationsviral infectionsReferences1. Tombacz I, Weissman D, Pardi N. Vaccination with messenger RNA: a promising alternative DNA vaccination. In: Vaccines. Methods in Molecular Biology (Volume 2197). Sousa  (Ed.). Humana, NY, USA, 13–31 (2021).Crossref, Google Scholar2. Maugeri M, Nawaz Papadimitriou A et al. Linkage between endosomal escape LNP-mRNA loading into EVs transport other cells. Nat. Commun. 10, 4333 (2019).Crossref, Medline, CAS, Scholar3. Walsh EE, Frenck RW Jr, Falsey AR Safety immunogenicity two RNA-based Covid-19 vaccine candidates. Engl. J. Med. 383(25), 2439–2450 (2020).Crossref, Scholar4. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/Google Scholar5. Hoffmann Kleine-Weber H, Schroeder S SARS-CoV-2 cell entry depends on ACE2 TMPRSS2 is blocked clinically proven protease inhibitor. Cell 181(2), 271–280 Scholar6. Huang C, Wang Y, Li X Clinical features patients infected 2019 novel coronavirus Wuhan, China. Lancet 395(10223), 497–506 Scholar7. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies cancer immunotherapy. Rev. Drug. Discov. 18(3), 175–196 Scholar8. Santos PM, Butterfield LH. Dendritic cell-based vaccines. Immunol. 200(2), 443–449 (2018).Crossref, Scholar9. Ni J, Song B the effective immunotherapy breast cancer. Biomed. Pharmacother. 126, 110046 Scholar10. Cedolini Bertozzi S, Londero AP Type diagnosis, screening, survival. Clin. Breast Cancer 14(4), 235–240 (2014).Crossref, Scholar11. Van Zelst JCM, Vreemann Witt HJ Multireader study diagnostic accuracy ultrafast magnetic resonance imaging screening. Invest. Radiol. 53(10), 579–586 Scholar12. Lelyveld VS, Brustad E, Arnold FH, Jasanoff A. Metal-substituted protein MRI contrast agents engineered enhanced relaxivity ligand sensitivity. Am. Chem. Soc. 133(4), 649–651 (2011).Crossref, Scholar13. Lee Heo SH, IH Presence tertiary lymphoid structures determines level tumor-infiltrating lymphocytes primary metastasis. Mod. Pathol. 32(1), 70–80 Scholar14. Zare Rajabibazl Rasooli I Production nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP Int. Biol. Marker. 29(2), E169–E179 Scholar15. Robbiani DF, Gaebler Muecksch F Convergent antibody responses convalescent individuals. Nature 584(7821), 437–442 Scholar16. Report Cancer: Setting Priorities, Investing Wisely Providing Care All. Organization, Geneva, Switzerland (2020).Google Scholar17. Vollmer Krieg AM. Immunotherapeutic applications CpG oligodeoxynucleotide TLR9 agonists. Adv. Deliv. 61(3), 195–204 (2009).Crossref, ScholarFiguresReferencesRelatedDetails Vol. Follow us social media latest updates Metrics Downloaded 91 times History Received 28 December 2020 Accepted 18 January Published online February 2021 print Information© Future Medicine LtdKeywordscancerdisease infectionsFinancial competing interests disclosureThe authors have no relevant affiliations or financial involvement any organization entity interest conflict subject matter materials discussed manuscript. This includes employment, consultancies, honoraria, stock ownership options, expert testimony, grants patents received pending, royalties.No writing assistance was utilized production manuscript.PDF download